Melane Sampson, Author at BioTuesdays

Developments

Xenetic and Santersus enter into definitive share exchange agreement

Xenetic Biosciences (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire closely held Santersus in an all-stock transaction, subject to stockholder approval. The combined company is expected...

September 17, 2026

Developments

BioPorto initiates patient enrollment in adult urine NGAL validation study

BioPorto (CPH: BIOPOR) has announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to...

September 17, 2026

Developments

Firefly’s Evoke platform selected for Radial’s AI-native brain medicine operating system

Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic collaboration with closely held Radial, operator of the U.S.’s largest network of brain medicine clinics, to pursue the integration of Firefly’s...

September 17, 2026

Developments

FDA grants Armata Breakthrough Therapy designation for AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate, for...

September 14, 2026

Developments

Perspective and Merck collaborate on study of combined therapies in FAP-α solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced a clinical trial collaboration agreement with Merck (NYSE: MRK) to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda...

September 14, 2026

Developments

Q32 Bio names Drs. José Trevejo as CMO and Ellie Hershberger as CDO

Q32 Bio (NASDAQ: QTTB) has announced the appointment of José Trevejo, MD, PhD, as chief medical officer (CMO) and Ellie Hershberger, PharmD, as chief development officer (CDO). Prior to joining Q32 Bio, Dr. Trevejo...

September 14, 2026

Developments

First AUD patients enrolled in Clearmind’s psychedelic-based treatment trial

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of the first patients with alcohol use disorder (AUD) in its ongoing clinical trial evaluating CMND-100, the company’s proprietary psychedelic-based...

September 11, 2026

Developments

IMUNON enters CRADA with NCI to advance gene-based immunotherapy

IMUNON (NASDAQ: IMNN) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to support further clinical and non-clinical development of IMNN-001, the...

September 10, 2026

Developments

MolDX issues Bionano proposed LCD

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics (NASDAQ: BNGO) has announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors...

September 10, 2026

Developments

Ocumetics initiates patient recruitment for next-gen lens study

Ocumetics Technology (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) has announced that its clinical facility in Mexico City has initiated the patient recruitment process for Group Two of the company’s ongoing human clinical...

September 8, 2026

Author - Melane Sampson

Xenetic and Santersus enter into definitive share exchange agreement

BioPorto initiates patient enrollment in adult urine NGAL validation study

Firefly’s Evoke platform selected for Radial’s AI-native brain medicine operating system

FDA grants Armata Breakthrough Therapy designation for AP-SA02

Perspective and Merck collaborate on study of combined therapies in FAP-α solid tumors

Q32 Bio names Drs. José Trevejo as CMO and Ellie Hershberger as CDO

First AUD patients enrolled in Clearmind’s psychedelic-based treatment trial

IMUNON enters CRADA with NCI to advance gene-based immunotherapy

MolDX issues Bionano proposed LCD

Ocumetics initiates patient recruitment for next-gen lens study

Subscribe